1. Home
  2. NRIX vs EXPI Comparison

NRIX vs EXPI Comparison

Compare NRIX & EXPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc. Common stock

NRIX

Nurix Therapeutics Inc. Common stock

HOLD

Current Price

$19.57

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo eXp World Holdings Inc.

EXPI

eXp World Holdings Inc.

HOLD

Current Price

$10.44

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
EXPI
Founded
2009
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
NRIX
EXPI
Price
$19.57
$10.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
1
Target Price
$26.08
$12.00
AVG Volume (30 Days)
1.8M
1.8M
Earning Date
01-27-2026
11-06-2025
Dividend Yield
N/A
1.89%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$83,687,000.00
$4,678,653,000.00
Revenue This Year
$58.38
$6.03
Revenue Next Year
N/A
$5.37
P/E Ratio
N/A
N/A
Revenue Growth
48.32
5.12
52 Week Low
$8.18
$6.90
52 Week High
$22.95
$13.66

Technical Indicators

Market Signals
Indicator
NRIX
EXPI
Relative Strength Index (RSI) 70.09 43.92
Support Level $16.02 $11.03
Resistance Level $22.50 $11.39
Average True Range (ATR) 1.33 0.43
MACD 0.32 -0.07
Stochastic Oscillator 72.19 16.49

Price Performance

Historical Comparison
NRIX
EXPI

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About EXPI eXp World Holdings Inc.

eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.

Share on Social Networks: